Intratio
Loading...
Skip to main content
Model output · Signal date Oct. 16, 2026

Daily Signals

2758 companies scored · Total · absolute moveSwitch to Alpha · 30D 90D

Signal date 2026-10-16 Cut-offs from the 2026-10-16 run
Companies scored 2758 IC ≥ 0 · market cap ≥ $100M
Median forecast +2.43% Total · 90D
Long–short spread +6.48% Strong Buy minus Strong Sell, mean
Median IC 0.27 Spearman · 90D
Rating changes ▲ 166 ▼ 383 vs the previous run
Cross-section

Distribution of the day's forecasts

90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Signals · All

296 companies

Sorted by market cap ↓ · forecast rankings are part of the paid plans

# Ticker Sector IC Mkt cap Rating 30D 90D Δ
201 NGNENeurogene Inc. Life Sciences 0.03 $465M Unlock rating and forecasts
202 ENTXEntera Bio Ltd. Life Sciences 0.09 $464M Unlock rating and forecasts
203 RGNXREGENXBIO Inc. Life Sciences 0.03 $457M Unlock rating and forecasts
204 ARVNARVINAS, INC. Life Sciences 0.27 $456M Unlock rating and forecasts
205 ALLOAllogene Therapeutics, Inc. Life Sciences 0.04 $453M Unlock rating and forecasts
206 NIKANIKA PHARMACEUTICALS, INC Life Sciences 0.17 $431M Neutral -0.80% +2.67% new
207 PRTAPROTHENA CORP PUBLIC LTD CO Life Sciences 0.28 $429M Unlock rating and forecasts
208 AUTLAutolus Therapeutics plc Life Sciences 0.30 $426M Unlock rating and forecasts
209 OVIDOvid Therapeutics Inc. Life Sciences 0.06 $420M Unlock rating and forecasts
210 TLRYTilray Brands, Inc. Life Sciences 0.15 $414M Neutral +0.69% +2.44% ·
211 ASMBASSEMBLY BIOSCIENCES, INC. Life Sciences 0.06 $409M Unlock rating and forecasts
212 EIKNEikon Therapeutics, Inc. Life Sciences 0.32 $402M Unlock rating and forecasts
213 PROKPROKIDNEY CORP. Life Sciences 0.02 $400M Unlock rating and forecasts
214 CAPRCAPRICOR THERAPEUTICS, INC. Life Sciences 0.45 $390M Unlock rating and forecasts
215 MYGNMYRIAD GENETICS INC Life Sciences 0.39 $381M Unlock rating and forecasts
216 TKNOAlpha Teknova, Inc. Life Sciences 0.37 $380M Unlock rating and forecasts
217 ZURAZura Bio Ltd Life Sciences 0.19 $372M Unlock rating and forecasts
218 EDITEditas Medicine, Inc. Life Sciences 0.20 $361M Unlock rating and forecasts
219 KYTXKyverna Therapeutics, Inc. Life Sciences 0.62 $351M Unlock rating and forecasts
220 INDPIndaptus Therapeutics, Inc. Life Sciences 0.09 $350M Neutral +0.72% +2.57% ▲ 1
221 FENCFENNEC PHARMACEUTICALS INC. Life Sciences 0.37 $350M Unlock rating and forecasts
222 RZLTRezolute, Inc. Life Sciences 0.37 $346M Unlock rating and forecasts
223 CCCCC4 Therapeutics, Inc. Life Sciences 0.31 $340M Unlock rating and forecasts
224 PRLDPrelude Therapeutics Inc Life Sciences 0.04 $334M Unlock rating and forecasts
225 RLMDRELMADA THERAPEUTICS, INC. Life Sciences 0.37 $331M Unlock rating and forecasts
226 VTVTvTv Therapeutics Inc. Life Sciences 0.14 $329M Neutral +0.93% +2.89% ▼ 1
227 EBSEmergent BioSolutions Inc. Life Sciences 0.56 $327M Unlock rating and forecasts
228 ENTAENANTA PHARMACEUTICALS INC Life Sciences 0.52 $323M Unlock rating and forecasts
229 IRDOpus Genetics, Inc. Life Sciences 0.29 $319M Unlock rating and forecasts
230 TTRXTurn Therapeutics Inc. Life Sciences 0.28 $315M Unlock rating and forecasts
231 IKTInhibikase Therapeutics, Inc. Life Sciences 0.07 $300M Unlock rating and forecasts
232 ARCTArcturus Therapeutics Holdings Inc. Life Sciences 0.19 $294M Unlock rating and forecasts
233 USNAUSANA HEALTH SCIENCES INC Life Sciences 0.28 $287M Unlock rating and forecasts
234 ARTVArtiva Biotherapeutics, Inc. Life Sciences 0.25 $286M Unlock rating and forecasts
235 FULCFulcrum Therapeutics, Inc. Life Sciences 0.01 $278M Unlock rating and forecasts
236 CYPHCYPHERPUNK TECHNOLOGIES INC. Life Sciences 0.16 $277M Unlock rating and forecasts
237 SRZNSurrozen, Inc./DE Life Sciences 0.17 $276M Unlock rating and forecasts
238 AGENAGENUS INC Life Sciences 0.59 $272M Unlock rating and forecasts
239 ELTPELITE PHARMACEUTICALS INC /NV/ Life Sciences 0.23 $269M Unlock rating and forecasts
240 OCGNOcugen, Inc. Life Sciences 0.42 $265M Unlock rating and forecasts
241 ACBAURORA CANNABIS INC Life Sciences 0.16 $253M Neutral +1.09% +3.25% ▼ 1
242 IPSCCentury Therapeutics, Inc. Life Sciences 0.37 $248M Unlock rating and forecasts
243 CATXPerspective Therapeutics, Inc. Life Sciences 0.10 $248M Unlock rating and forecasts
244 LABSTANDARD BIOTOOLS INC. Life Sciences 0.21 $247M Unlock rating and forecasts
245 PALIPALISADE BIO, INC. Life Sciences 0.13 $246M Unlock rating and forecasts
246 VNDAVanda Pharmaceuticals Inc. Life Sciences 0.28 $244M Unlock rating and forecasts
247 LFCRLIFECORE BIOMEDICAL, INC. \DE\ Life Sciences 0.30 $242M Unlock rating and forecasts
248 ABEOABEONA THERAPEUTICS INC. Life Sciences 0.09 $240M Unlock rating and forecasts
249 CABACabaletta Bio, Inc. Life Sciences 0.04 $239M Unlock rating and forecasts
250 AMRNAMARIN CORP PLC\UK Life Sciences 0.05 $238M Neutral +0.85% +2.46% ·
201–250 of 296 Previous Next
Since the previous run

Rating changes

▲ 166▼ 383
Which companies were upgraded or downgraded is part of the paid plans.
Next step

Unlock the full ranking

Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.

See plans Create a free account
Methodology

Ratings are relative: the forecasts of the latest complete daily run (2026-10-16) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected absolute price move over the horizon, market included. This is the number a price target is built from. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.